Payment overview · 2025
General Payments
$449.13
19 reported records · 11 companies
Healthcare provider profile · identity verified
Thomas J Vaughan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DALTON, MA · NPI 1730275140
Verified facts
What the public records show
CMS Open Payments records show Thomas J Vaughan, MD received $449.13 in general payments during 2025 across 19 reported records.
PFIZER INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.30 | 22.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.33 | 15.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.54 | 13.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $46.26 | 10.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 10.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.12 | 7.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.13 | 5.4% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $20.56 | 4.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.88 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.38 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.63 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $404.13 | 18 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.30 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.32 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.14 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.12 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 359 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
359 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1164 | 297 |
| Lisinopril | Lisinopril | 744 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 735 | 189 |
| Losartan Potassium | Losartan Potassium | 520 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 515 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 513 | 125 |
| Lorazepam | Lorazepam | 455 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 121 |
| Omeprazole | Omeprazole | 387 | 108 |
| Eliquis | Apixaban | 359 | 60 |
| Gabapentin | Gabapentin | 331 | 64 |
| Metformin Hcl | Metformin Hcl | 307 | 85 |
| Simvastatin | Simvastatin | 302 | 70 |
| Furosemide | Furosemide | 260 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 256 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 59 |
| Allopurinol | Allopurinol | 243 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 53 |
| Metformin Hcl Er | Metformin Hcl | 202 | 53 |
| Prednisone | Prednisone | 178 | 54 |
| Clonazepam | Clonazepam | 171 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 163 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 23 |
| Sertraline Hcl | Sertraline Hcl | 140 | 36 |
| Chlorthalidone | Chlorthalidone | 138 | 37 |
| Tramadol Hcl | Tramadol Hcl | 138 | 26 |
| Famotidine | Famotidine | 136 | 34 |
| Xarelto | Rivaroxaban | 132 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 33 |
| Carvedilol | Carvedilol | 120 | 30 |
| Montelukast Sodium | Montelukast Sodium | 120 | 24 |
| Atenolol | Atenolol | 116 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 29 |
| Warfarin Sodium | Warfarin Sodium | 112 | 25 |
| Ramipril | Ramipril | 106 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 28 |
| Alprazolam | Alprazolam | 99 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 19 |
| Diazepam | Diazepam | 98 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 26 |
| Glimepiride | Glimepiride | 94 | 23 |
| Trazodone Hcl | Trazodone Hcl | 94 | 26 |
| Indapamide | Indapamide | 93 | 21 |
| Alendronate Sodium | Alendronate Sodium | 90 | 27 |
| Finasteride | Finasteride | 90 | 25 |
| Valsartan | Valsartan | 84 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 14 |
| Buspirone Hcl | Buspirone Hcl | 80 | 16 |
| Trulicity | Dulaglutide | 76 | suppressed |
| Spironolactone | Spironolactone | 71 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 22 |
| Mirtazapine | Mirtazapine | 67 | 12 |
| Donepezil Hcl | Donepezil Hcl | 66 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | suppressed |
| Jantoven | Warfarin Sodium | 63 | 12 |
| Methadone Hcl | Methadone Hcl | 61 | suppressed |
| Potassium Chloride | Potassium Chloride | 60 | 18 |
| Synthroid | Levothyroxine Sodium | 59 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 15 |
| Torsemide | Torsemide | 57 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | 13 |
| Baclofen | Baclofen | 54 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Labetalol Hcl | Labetalol Hcl | 51 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 11 |
| Lamotrigine | Lamotrigine | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 11 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 12 |
| Fluconazole | Fluconazole | 42 | 12 |
| Levetiracetam | Levetiracetam | 41 | 11 |
| Terazosin Hcl | Terazosin Hcl | 41 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 14 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Azithromycin | Azithromycin | 34 | 22 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 16 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Metronidazole | Metronidazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Testosterone | Testosterone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vyndamax | Tafamidis | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Concerta | Methylphenidate Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $449.13 · 19 records | PFIZER INC. | Attruby, CAPVAXIVE, ELIQUIS, EVENITY, GARDASIL 9, GVOKE HYPOPEN, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, WAINUA, Wegovy, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error